212 related articles for article (PubMed ID: 34716207)
21. Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients.
Mastrangelo S; Rivetti S; Triarico S; Romano A; Attinà G; Maurizi P; Ruggiero A
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884452
[TBL] [Abstract][Full Text] [Related]
22. Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition.
Voeller J; Erbe AK; Slowinski J; Rasmussen K; Carlson PM; Hoefges A; VandenHeuvel S; Stuckwisch A; Wang X; Gillies SD; Patel RB; Farrel A; Rokita JL; Maris J; Hank JA; Morris ZS; Rakhmilevich AL; Sondel PM
J Immunother Cancer; 2019 Dec; 7(1):344. PubMed ID: 31810498
[TBL] [Abstract][Full Text] [Related]
23. Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.
Navid F; Sondel PM; Barfield R; Shulkin BL; Kaufman RA; Allay JA; Gan J; Hutson P; Seo S; Kim K; Goldberg J; Hank JA; Billups CA; Wu J; Furman WL; McGregor LM; Otto M; Gillies SD; Handgretinger R; Santana VM
J Clin Oncol; 2014 May; 32(14):1445-52. PubMed ID: 24711551
[TBL] [Abstract][Full Text] [Related]
24. Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.
Siebert N; Seidel D; Eger C; Brackrock D; Reker D; Schmidt M; Lode HN
J Immunol Methods; 2013 Dec; 398-399():51-9. PubMed ID: 24055592
[TBL] [Abstract][Full Text] [Related]
25. Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma.
Eger C; Siebert N; Seidel D; Zumpe M; Jüttner M; Brandt S; Müller HP; Lode HN
PLoS One; 2016; 11(3):e0150479. PubMed ID: 26967324
[TBL] [Abstract][Full Text] [Related]
26. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
Seitz CM; Flaadt T; Mezger M; Lang AM; Michaelis S; Katz M; Syring D; Joechner A; Rabsteyn A; Siebert N; Troschke-Meurer S; Zumpe M; Lode HN; Yang SF; Atar D; Mast AS; Scheuermann S; Heubach F; Handgretinger R; Lang P; Schlegel P
Front Immunol; 2021; 12():690467. PubMed ID: 34367149
[TBL] [Abstract][Full Text] [Related]
27. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.
Shibina A; Seidel D; Somanchi SS; Lee DA; Stermann A; Maurer BJ; Lode HN; Reynolds CP; Huebener N
J Mol Med (Berl); 2013 Apr; 91(4):459-72. PubMed ID: 23052481
[TBL] [Abstract][Full Text] [Related]
28. 64Cu-p-NH2-Bn-DOTA-hu14.18K322A, a PET radiotracer targeting neuroblastoma and melanoma.
Vavere AL; Butch ER; Dearling JL; Packard AB; Navid F; Shulkin BL; Barfield RC; Snyder SE
J Nucl Med; 2012 Nov; 53(11):1772-8. PubMed ID: 23064212
[TBL] [Abstract][Full Text] [Related]
29. Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells.
Fisher JP; Flutter B; Wesemann F; Frosch J; Rossig C; Gustafsson K; Anderson J
Oncoimmunology; 2016; 5(1):e1025194. PubMed ID: 26942051
[TBL] [Abstract][Full Text] [Related]
30. The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of
Pilgrim AA; Jonus HC; Ho A; Cole AC; Shim J; Goldsmith KC
Oncoimmunology; 2023; 12(1):2240678. PubMed ID: 37554309
[TBL] [Abstract][Full Text] [Related]
31. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
Yu AL; Gilman AL; Ozkaynak MF; London WB; Kreissman SG; Chen HX; Smith M; Anderson B; Villablanca JG; Matthay KK; Shimada H; Grupp SA; Seeger R; Reynolds CP; Buxton A; Reisfeld RA; Gillies SD; Cohn SL; Maris JM; Sondel PM;
N Engl J Med; 2010 Sep; 363(14):1324-34. PubMed ID: 20879881
[TBL] [Abstract][Full Text] [Related]
32. Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1.
Mabe NW; Huang M; Dalton GN; Alexe G; Schaefer DA; Geraghty AC; Robichaud AL; Conway AS; Khalid D; Mader MM; Belk JA; Ross KN; Sheffer M; Linde MH; Ly N; Yao W; Rotiroti MC; Smith BAH; Wernig M; Bertozzi CR; Monje M; Mitsiades CS; Majeti R; Satpathy AT; Stegmaier K; Majzner RG
Nat Cancer; 2022 Aug; 3(8):976-993. PubMed ID: 35817829
[TBL] [Abstract][Full Text] [Related]
33. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies.
Cheung NK; Canete A; Cheung IY; Ye JN; Liu C
Int J Cancer; 1993 May; 54(3):499-505. PubMed ID: 8509225
[TBL] [Abstract][Full Text] [Related]
34. Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma.
Chan GC; Chan CM
Biomolecules; 2022 Feb; 12(3):. PubMed ID: 35327550
[TBL] [Abstract][Full Text] [Related]
35. Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody.
Siebert N; Seidel D; Eger C; Jüttner M; Lode HN
PLoS One; 2014; 9(9):e107692. PubMed ID: 25226154
[TBL] [Abstract][Full Text] [Related]
36. Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO.
Siebert N; Eger C; Seidel D; Jüttner M; Lode HN
J Immunol Methods; 2014 May; 407():108-15. PubMed ID: 24727144
[TBL] [Abstract][Full Text] [Related]
37. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
[TBL] [Abstract][Full Text] [Related]
38. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
[TBL] [Abstract][Full Text] [Related]
39. Anti-GD2 antibody and Vorinostat immunocombination therapy is highly effective in an aggressive orthotopic neuroblastoma model.
van den Bijgaart RJE; Kroesen M; Brok IC; Reijnen D; Wassink M; Boon L; Hoogerbrugge PM; Adema GJ
Oncoimmunology; 2020 Sep; 9(1):1817653. PubMed ID: 33457098
[TBL] [Abstract][Full Text] [Related]
40. Reduction of CD11b
Siebert N; Zumpe M; von Lojewski L; Troschke-Meurer S; Marx M; Lode HN
Oncoimmunology; 2020 Oct; 9(1):1836768. PubMed ID: 33150046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]